ClinicalTrials.gg
CompletedNCT03955211Updated Nov 13, 2026Results posted

PK and Safety After C-Section

A Phase 2 interventional study of HTX-011 and ZYNRELEF kit components for administration in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Heron Therapeutics · Phase 2, Interventional, and Prevention

Updated Nov 13, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
320th of 364
25 · median 70
Started
2019
with 34 others
Phase 2
43 of 364
4 open now
Registered
182nd of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 320th largest by enrollment, is one of 35 that started in 2019, is one of 43 in phase 2, and was the 182nd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The main goal of the study was to measure the amount of the active ingredients and other components of HTX-011 in plasma and expressed breast milk over time following postpartum administration in women undergoing a planned C-section. The study also looked at the safety of HTX-011 in these women.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • postoperative pain
  • caesarean section
  • C-section
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is expected, at the time of Screening visit, to deliver a single neonate.
  • Is scheduled to undergo a planned C-section surgery with a low transverse skin incision (eg, Pfannenstiel).
  • Has (ASA) Physical Status of I, II, or III.
  • Agrees to practice abstinence or use double-barrier in the event of sexual activity and commits to the use of an acceptable form of birth control for 30 days after HTX-011 administration.
  • Agrees to refrain from the use of breast milk from this pregnancy in any manner.

Exclusion criteria

Exclusion Criteria:

  • Has planned to breastfeed her neonate at any time during the 28-day period after HTX-011 administration.
  • Has had a prior full-term pregnancy with unsuccessful breast milk expression.
  • Has a planned concurrent surgical procedure.
  • Has a or a known or suspected history of or idiosyncratic reaction to required study medications.
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
  • Has been administered systemic within 5 half-lives or 10 days prior to administration of study drug.
  • Has initiated treatment with study medications within 1 month prior to study drug administration that can impact pain control.
  • Has taken any NSAIDs within least 10 days prior to the scheduled surgery.
  • Has current significant placental abnormality/complications including, but not limited to, placenta previa or placenta accreta.
  • Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
  • Has uncontrolled anxiety, psychiatric, or neurological disorder.
  • Had a in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.
  • Previously participated in an HTX-011 study.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half-lives.
  • Weight is \<50 kg at the time of Screening visit.
  • In the Investigator's judgment, subject is likely to have been morbidly obese prior to her pregnancy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    HTX-011 300 mg/9 mg

    HTX-011 (bupivacaine/meloxicam) 300 mg/9 mg via instillation

    Drug: HTX-011 · Device: ZYNRELEF kit components for administration

  • Experimental
    HTX-011 400 mg/12 mg + MMA

    HTX-011 (bupivacaine/meloxicam) 400 mg/12 mg via instillation + oral (PO) non-opioid multimodal analgesic (MMA) regimen

    Drug: HTX-011 · Device: ZYNRELEF kit components for administration · Drug: MMA regimen

Interventions

  • DrugHTX-011

    Drug pages: Bupivacaine · Meloxicam

    bupivacaine/meloxicam extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits

    Also known as: ZYNRELEF

  • DeviceZYNRELEF kit components for administration

    ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps.

  • DrugMMA regimen

    Drug pages: Ibuprofen · Acetaminophen

    PO ibuprofen 400 mg every 6 hours (q6h), alternating with PO acetaminophen 975 mg to 1 g q6h, alternating the 2 medications so that an analgesic was taken approximately every 3 hours (q3h) while the subject was awake

    Also known as: ibuprofen, acetaminophen

06

What researchers measure

Primary outcomes

  1. Bupivacaine Plasma Cmax

    Maximum plasma concentration of bupivacaine

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  2. Bupivacaine Plasma Tmax

    Time to maximum concentration of bupivacaine in plasma

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  3. Bupivacaine Plasma t1/2

    Half life of bupivacaine in plasma

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  4. Bupivacaine Plasma AUCinf

    Area under the bupivacaine plasma concentration-time curve from Time 0 extrapolated to infinity

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  5. Bupivacaine Breast Milk Cmax

    Maximum concentration of bupivacaine in breast milk

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  6. Bupivacaine Breast Milk Tmax

    Time to maximum concentration of bupivacaine in breast milk

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  7. Bupivacaine Breast Milk AUClast

    Area under the bupivacaine breast milk concentration-time curve from Time 0 to time of last quantifiable concentration

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  8. Meloxicam Plasma Cmax

    Maximum plasma concentrations of meloxicam

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  9. Meloxicam Plasma Tmax

    Time to maximum meloxicam plasma concentration in plasma

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  10. Meloxicam Plasma t1/2

    Half-life of meloxicam in plasma

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  11. Meloxicam Plasma AUCinf

    Area under the meloxicam plasma concentration-time curve from Time 0 extrapolated to infinity

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  12. Meloxicam Breast Milk Cmax

    Maximum concentration of meloxicam in breast milk

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  13. Meloxicam Breast Milk Tmax

    Time to maximum meloxicam concentration in breast milk

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

  14. Meloxicam Breast Milk AUClast

    Area under the meloxicam breast milk concentration-time curve from Time 0 to time of last quantifiable concentration

    Time frame: Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Started1411
Completed1411
Not completed00

Outcome measures

PrimaryBupivacaine Plasma Cmax

Maximum plasma concentration of bupivacaine

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · ng/mL
Bupivacaine Plasma Cmax
ng/mLHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Bupivacaine Plasma Cmax238 ± 59.5291 ± 69.6
PrimaryBupivacaine Plasma Tmax

Time to maximum concentration of bupivacaine in plasma

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Median · hours
Bupivacaine Plasma Tmax
hoursHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Bupivacaine Plasma Tmax24.02 (4.08 to 48.93)23.70 (1.07 to 48.22)
PrimaryBupivacaine Plasma t1/2

Half life of bupivacaine in plasma

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · hours
Bupivacaine Plasma t1/2
hoursHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Bupivacaine Plasma t1/29.64 ± 2.499.95 ± 1.61
PrimaryBupivacaine Plasma AUCinf

Area under the bupivacaine plasma concentration-time curve from Time 0 extrapolated to infinity

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · h∙ng/mL
Bupivacaine Plasma AUCinf
h∙ng/mLHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Bupivacaine Plasma AUCinf13300 ± 322017500 ± 4810
PrimaryBupivacaine Breast Milk Cmax

Maximum concentration of bupivacaine in breast milk

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · ng/mL
Bupivacaine Breast Milk Cmax
ng/mLHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Bupivacaine Breast Milk Cmax21.1 ± 12.440.1 ± 25.4
PrimaryBupivacaine Breast Milk Tmax

Time to maximum concentration of bupivacaine in breast milk

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Median · hours
Bupivacaine Breast Milk Tmax
hoursHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Bupivacaine Breast Milk Tmax43.41 (9.45 to 106.13)23.50 (9.95 to 59.93)
PrimaryBupivacaine Breast Milk AUClast

Area under the bupivacaine breast milk concentration-time curve from Time 0 to time of last quantifiable concentration

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · h∙ng/mL
Bupivacaine Breast Milk AUClast
h∙ng/mLHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Bupivacaine Breast Milk AUClast769 ± 5321600 ± 1040
PrimaryMeloxicam Plasma Cmax

Maximum plasma concentrations of meloxicam

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · ng/mL
Meloxicam Plasma Cmax
ng/mLHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Meloxicam Plasma Cmax75.2 ± 31.7114 ± 48.6
PrimaryMeloxicam Plasma Tmax

Time to maximum meloxicam plasma concentration in plasma

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Median · hours
Meloxicam Plasma Tmax
hoursHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Meloxicam Plasma Tmax35.57 (9.62 to 73.03)60.08 (8.45 to 72.80)
PrimaryMeloxicam Plasma t1/2

Half-life of meloxicam in plasma

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · hours
Meloxicam Plasma t1/2
hoursHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Meloxicam Plasma t1/217.9 ± 5.9220.2 ± 7.46
PrimaryMeloxicam Plasma AUCinf

Area under the meloxicam plasma concentration-time curve from Time 0 extrapolated to infinity

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · h∙ng/mL
Meloxicam Plasma AUCinf
h∙ng/mLHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Meloxicam Plasma AUCinf5940 ± 23209620 ± 4540
PrimaryMeloxicam Breast Milk Cmax

Maximum concentration of meloxicam in breast milk

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · ng/mL
Meloxicam Breast Milk Cmax
ng/mLHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Meloxicam Breast Milk Cmax1.92 ± 1.003.06 ± 2.70
PrimaryMeloxicam Breast Milk Tmax

Time to maximum meloxicam concentration in breast milk

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Median · hours
Meloxicam Breast Milk Tmax
hoursHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Meloxicam Breast Milk Tmax59.23 (21.02 to 106.13)58.40 (11.63 to 83.45)
PrimaryMeloxicam Breast Milk AUClast

Area under the meloxicam breast milk concentration-time curve from Time 0 to time of last quantifiable concentration

Time frame:
Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Reported as:
Mean · h∙ng/mL
Meloxicam Breast Milk AUClast
h∙ng/mLHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
Meloxicam Breast Milk AUClast86.7 ± 59.8161 ± 186

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HTX-011 300 mg/9 mg0/14 (0%)1/14 (7.1%)12/14 (85.7%)
HTX-011 400 mg/12 mg + MMA0/11 (0%)1/11 (9.1%)8/11 (72.7%)
Most frequent serious events
Most frequent serious events
EventHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
PneumoniaInfections and infestations0/141/11
Cardiac failure congestiveCardiac disorders0/141/11
Gestational hypertensionPregnancy, puerperium and perinatal conditions1/140/11
Most frequent other events
Showing 10 of 26
Most frequent other events
EventHTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMA
ConstipationGastrointestinal disorders6/142/11
FlatulenceGeneral disorders4/143/11
PruritusSkin and subcutaneous tissue disorders2/143/11
NauseaGastrointestinal disorders3/140/11
Anaemia postoperativeInjury, poisoning and procedural complications3/142/11
AnaemiaBlood and lymphatic system disorders0/141/11
HypokalaemiaMetabolism and nutrition disorders0/141/11
HeadacheNervous system disorders0/141/11
DyspnoeaRespiratory, thoracic and mediastinal disorders0/141/11
Productive coughRespiratory, thoracic and mediastinal disorders0/141/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)HTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMATotal
Mean29.5 ± 5.5625.9 ± 4.0127.9 ± 5.17
Sex: Female, Male
Sex: Female, Male(Participants)HTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMATotal
Female141125
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American235
White12820
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)HTX-011 300 mg/9 mgHTX-011 400 mg/12 mg + MMATotal
United States141125
08

Study locations

4 sites
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • Sharp Mary Birch Hospital for Women and Newborns
    San Diego, California 92123, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • UPMC Magee-Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Dec 2021, 29 months.

Results were first posted in Oct 2026, 4 years 10 months after primary completion.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 29 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
May 20, 2019
StartActual
Jun 24, 2019
Primary completionActual
Dec 3, 2021
CompletionActual
Dec 27, 2021
Results first posted
Oct 27, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 27, 2026 · revised Nov 13, 2026
Interventions
Added Device: ZYNRELEF kit components for administration·Drug: MMA regimen; removed Drug: HTX-011·Device: Luer Lock Applicator·Drug: Ibuprofen·Drug: Acetaminophen. Arms added: HTX-011 300 mg/9 mg·HTX-011 400 mg/12 mg + MMA; arms removed: Treatment Group 1·Treatment Group 2
Oct 27, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 27, 2026
  • AddedBupivacaine Plasma CmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedBupivacaine Plasma TmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedBupivacaine Plasma t1/2Time frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedBupivacaine Plasma AUCinfTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedBupivacaine Breast Milk CmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedBupivacaine Breast Milk TmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedBupivacaine Breast Milk AUClastTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedMeloxicam Plasma CmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedMeloxicam Plasma TmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedMeloxicam Plasma t1/2Time frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedMeloxicam Plasma AUCinfTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedMeloxicam Breast Milk CmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedMeloxicam Breast Milk TmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • AddedMeloxicam Breast Milk AUClastTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • RemovedMaximum plasma concentration (Cmax) of bupivacaine, meloxicam, dimethyl sulfoxide (DMSO) and HTX-011 polymerTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • RemovedTime of maximum plasma concentration (Tmax) of bupivacaine, meloxicam, DMSO and HTX-011 polymerTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • RemovedHalf life (t1/2) in plasma of bupivacaine, meloxicam, DMSO and HTX-011 polymerTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • RemovedHalf life (t1/2) in milk of bupivacaine, meloxicam, DMSO and HTX-011 polymerTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • RemovedAmount of analyte excreted in breast milk over time (Ae)Time frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
  • RemovedFraction of dose excreted in breast milk over time (Fe)Time frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
What changed on Nov 13, 2026
  • Time frameBupivacaine Plasma CmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameBupivacaine Plasma TmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameBupivacaine Plasma t1/2Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameBupivacaine Plasma AUCinfDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameBupivacaine Breast Milk CmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameBupivacaine Breast Milk TmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameBupivacaine Breast Milk AUClastDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameMeloxicam Plasma CmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameMeloxicam Plasma TmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameMeloxicam Plasma t1/2Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameMeloxicam Plasma AUCinfDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameMeloxicam Breast Milk CmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameMeloxicam Breast Milk TmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
  • Time frameMeloxicam Breast Milk AUClastDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
across 2 updates, Oct 27, 2026 – Nov 13, 2026
Documents
Secondary outcomes
2 removed
What changed in the outcomes
  • RemovedMean area under the curve of the NRS pain scores through 72 hours (AUC0-72).Time frame: 72 hours
  • RemovedIncidence of treatment-emergent adverse events (TEAEs).Time frame: 28 Days.
Oct 27, 2026
Title
HTX-011 Administration Study in Planned Caesarean Section Procedure→PK and Safety After C-Section
Oct 27, 2026
Show all 2 updates
  1. Nov 13, 2026
    Posted results revised
    Primary outcomes 14 time frame changed
    What changed in the outcomes
    • Time frameBupivacaine Plasma CmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameBupivacaine Plasma TmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameBupivacaine Plasma t1/2Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameBupivacaine Plasma AUCinfDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameBupivacaine Breast Milk CmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameBupivacaine Breast Milk TmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameBupivacaine Breast Milk AUClastDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameMeloxicam Plasma CmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameMeloxicam Plasma TmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameMeloxicam Plasma t1/2Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameMeloxicam Plasma AUCinfDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameMeloxicam Breast Milk CmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameMeloxicam Breast Milk TmaxDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    • Time frameMeloxicam Breast Milk AUClastDay 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2 → Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
    + 1 other change: verification date
  2. Oct 27, 2026
    Results posted
    Primary outcomes 14 added, 6 removed
    What changed in the outcomes
    • AddedBupivacaine Plasma CmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedBupivacaine Plasma TmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedBupivacaine Plasma t1/2Time frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedBupivacaine Plasma AUCinfTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedBupivacaine Breast Milk CmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedBupivacaine Breast Milk TmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedBupivacaine Breast Milk AUClastTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedMeloxicam Plasma CmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedMeloxicam Plasma TmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedMeloxicam Plasma t1/2Time frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedMeloxicam Plasma AUCinfTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedMeloxicam Breast Milk CmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedMeloxicam Breast Milk TmaxTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • AddedMeloxicam Breast Milk AUClastTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • RemovedMaximum plasma concentration (Cmax) of bupivacaine, meloxicam, dimethyl sulfoxide (DMSO) and HTX-011 polymerTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • RemovedTime of maximum plasma concentration (Tmax) of bupivacaine, meloxicam, DMSO and HTX-011 polymerTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • RemovedHalf life (t1/2) in plasma of bupivacaine, meloxicam, DMSO and HTX-011 polymerTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • RemovedHalf life (t1/2) in milk of bupivacaine, meloxicam, DMSO and HTX-011 polymerTime frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • RemovedAmount of analyte excreted in breast milk over time (Ae)Time frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    • RemovedFraction of dose excreted in breast milk over time (Fe)Time frame: Day 1 to Day 16 for Cohort 1; Day 1 to Day 11 for Cohort 2
    Secondary outcomes 2 removed
    What changed in the outcomes
    • RemovedMean area under the curve of the NRS pain scores through 72 hours (AUC0-72).Time frame: 72 hours
    • RemovedIncidence of treatment-emergent adverse events (TEAEs).Time frame: 28 Days.
    Interventions Added Device: ZYNRELEF kit components for administration·Drug: MMA regimen; removed Drug: HTX-011·Device: Luer Lock Applicator·Drug: Ibuprofen·Drug: Acetaminophen. Arms added: HTX-011 300 mg/9 mg·HTX-011 400 mg/12 mg + MMA; arms removed: Treatment Group 1·Treatment Group 2
    Title HTX-011 Administration Study in Planned Caesarean Section Procedure→PK and Safety After C-Section
    + 6 other changes: index terms, verification date, description, conditions, design details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03955211
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
May 20, 2019
Start date
Jun 24, 2019
Primary completion
Dec 3, 2021
Completion
Dec 27, 2021
Results posted
Oct 27, 2026
Last update
Nov 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Meloxicam

Start the discussion